Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 7722194)

1.

Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.

Leil TA, Frost C, Wang X, Pfister M, LaCreta F.

CPT Pharmacometrics Syst Pharmacol. 2014 Sep 17;3:e136. doi: 10.1038/psp.2014.34.

2.

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.

Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F.

Br J Clin Pharmacol. 2013 Feb;75(2):476-87. doi: 10.1111/j.1365-2125.2012.04369.x.

3.

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians.

Chest. 2012 Feb;141(2 Suppl):e44S-88S. doi: 10.1378/chest.11-2292. Review.

4.

Food-drug interactions.

Bushra R, Aslam N, Khan AY.

Oman Med J. 2011 Mar;26(2):77-83. doi: 10.5001/omj.2011.21.

5.

Warfarin and vitamin K intake in the era of pharmacogenetics.

Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H.

Br J Clin Pharmacol. 2010 Aug;70(2):164-70. doi: 10.1111/j.1365-2125.2010.03672.x. Review.

6.

Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding.

Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S.

Clin Pharmacol Ther. 2008 Nov;84(5):581-8. doi: 10.1038/clpt.2008.150. Epub 2008 Aug 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk